Goldman Sachs
HUMA icon

Goldman Sachs’s Humacyte HUMA Stock Holding History

Goldman Sachs’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458K Sell
586,524
-90,491
-13% -$83.9K ﹤0.01% 5751
2026
Q1 		$411K Buy
677,015
+249,777
+58% +$260K ﹤0.01% 5724
2025
Q4 		$410K Sell
427,238
-62,021
-13% -$87.8K ﹤0.01% 5715
2025
Q3 		$851K Sell
489,259
-148,416
-23% -$291K ﹤0.01% 5141
2025
Q2 		$1.33M Buy
637,675
+121,977
+24% +$234K ﹤0.01% 4496
2025
Q1 		$879K Sell
515,698
-112,028
-18% -$421K ﹤0.01% 4787
2024
Q4 		$3.17M Sell
627,726
-204,784
-25% -$1.01M ﹤0.01% 3899
2024
Q3 		$4.53M Buy
832,510
+70,935
+9% +$468K ﹤0.01% 3429
2024
Q2 		$3.66M Buy
761,575
+662,723
+670% +$3.45M ﹤0.01% 3440
2024
Q1 		$307K Sell
98,852
-1,854
-2% -$6.24K ﹤0.01% 4962
2023
Q4 		$286K Sell
100,706
-31,824
-24% -$81.7K ﹤0.01% 5031
2023
Q3 		$388K Buy
132,530
+57,981
+78% +$192K ﹤0.01% 4764
2023
Q2 		$213K Buy
74,549
+11,666
+19% +$42.1K ﹤0.01% 5157
2023
Q1 		$194K Buy
62,883
+7,289
+13% +$20.7K ﹤0.01% 5311
2022
Q4 		$117K Sell
55,594
-16,164
-23% -$49.1K ﹤0.01% 5444
2022
Q3 		$234K Buy
71,758
+28,855
+67% +$111K ﹤0.01% 5410
2022
Q2 		$138K Sell
42,903
-53,063
-55% -$295K ﹤0.01% 5760
2022
Q1 		$678K Buy
95,966
+18,281
+24% +$106K ﹤0.01% 5128
2021
Q4 		$563K Buy
+77,685
New +$768K ﹤0.01% 5298

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's HUMA Position: Q2 2026 in Review

Goldman Sachs reduced its Humacyte (HUMA) stake by 13% in Q2 2026, selling an estimated $83.9K and leaving 586,524 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #5751.

Goldman Sachs first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.53M in Q3 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Goldman Sachs held 586,524 shares of Humacyte worth $458K as of Q2 2026.
  • Goldman Sachs sold 90,491 Humacyte shares in Q2 2026, an estimated $83.9K.
  • Humacyte made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5751 holding.
  • Goldman Sachs first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Humacyte position peaked at $4.53M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.